We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Netscientific Plc | NSCI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 63.00 | 08:00:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 63.00 | 61.25 | 63.00 | 63.00 | 63.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 30/4/2024 20:13 by loafofbread EMV post says Ventive has just raised another £1M. Would suggest an RNS is due?06 November 2023 NetScientific plc ("NetScientific" or the "Company") Heat pump specialist Ventive secures c.GBP900,000 investment NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that its portfolio company Ventive has successfully closed a c.GBP900,000 investment ("Investment"). The Investment included GBP316,000 from existing shareholders and the conversion of two existing convertible loans (and interest thereon) valued at c.GBP600,000. This is the first closing as part of Ventive's proposed GBP1 million to GBP1.5 million investment programme, with further new investment anticipated prior to 30 April 2024 in one or more additional closings. This additional funding is complemented by ongoing non-dilutive funding from, amongst other grants awarded, a GBP1.5 million BEIS grant secured in 2022, as well as a recently awarded GBP100,000 UK Government grant focused on 'net zero HVAC' systems. The Investment was led and syndicated by EMV Capital, the Company's wholly owned venture capital and corporate finance firm. It follows the initial investment led and syndicated by EMV Capital that was announced (via RNS Reach) on 20 October 2022, where EMV Capital secured an initial c.16% stake in partial settlement of its fees. Since that initial investment, the value creation team of EMV Capital has worked closely with Ventive to stabilise and develop its business plan and product range. The proceeds of the Investment will support the completion of the design and test phase and factory build for Ventive's modular heat pumps, further enhancements to its passive air ventilation product range, and build-up of its marketing and sales capacity to drive sales of its existing product range. The Ventive balance sheet is also streamlined following the conversion of the convertible loans. Following completion of the Investment, the total equity holding of the NetScientific group in Ventive is 11.0% on a fully diluted basis, which includes the partial settlement of its corporate finance fees relating to the Investment. This holding equates to a post-investment fair value of GBP893,000, a substantial increase of 1,617% from the GBP52,000 reported as at 31 December 2022. In addition, following the introduction of investors to Ventive by EMV Capital under its capital efficient model, NetScientific's capital under advisory with Ventive is now 23.8% of the fully diluted share capital. |
Posted at 18/4/2024 12:16 by kingston78 There are increments in the value of the company's investments, without or with little further capital outlay, as those investments attract external funding.However, these increases in value are not realised and therefore many investors do not give it credence. Only when some or all of those investments are realised by selling them for cash will more investors recognise the true value of NSCI. Looking at past announcements, I feel that it will not be too far away when a total exit from one or more investments will take place. Watch this space for the share price to shoot up without warning. |
Posted at 05/4/2024 09:18 by loafofbread QBot 15%, EMV 32%USA and Europe. Q-Bot, the UK construction tech company that uses robotics and AI to insulate people’s homes, has strengthened its Board with the appointment of a new Executive Chair and a second Investment Director. Victor Vadaneaux has been appointed Executive Chair of Q-Bot. Victor has worked within B2B services, the engineering industry and the healthcare sector, and has extensive business and private equity experience of the UK, EU and US markets, including several successful exits. Malcolm Groat has been appointed an Investment Director of Q-Bot, to work alongside Dr Ilian Iliev, the company’s existing Investment Director. Malcolm has more than 25 years of experience as a Chair, NED, CFO, and CEO in the public and private markets. These senior board appointments significantly enhance Q-Bot’s capabilities and take place at an exciting time for the company and the construction industry. Using AI and robotics, Q-Bot’s insulation is deployed beneath suspended timber floors or to the underside of suspended concrete floors. In the UK alone, Q-Bot’s high performance retrofit insulation can help insulate the 8 to 12 million homes that have suspended floors and which are hard to treat using traditional forms of insulation. In the UK, Q-Bot’s customers include social housing landlords, energy companies and private homeowners. Internationally, the company has identified a further multi-billion market for robotics-based retrofit of insulation to residential homes in North America and North West Europe. Victor and Malcolm will help Q-Bot to scale its robotics-as-a-servic Their appointments have been facilitated by EMV Capital, a key investor in Q-Bot, and the company continues to draw on the value creation services provided by EMV Capital. |
Posted at 19/3/2024 19:36 by loafofbread Excellent Proactive Investor interview out today as well. |
Posted at 03/3/2024 18:36 by loafofbread Assume we will get an update on the Heat Pump prior to the start of Future build on Tuesday?Ventive is back showing our full suite of Building Services products: Intelligent Ventilation, Heating and Cooling solutions that autonomously react to the environment - creating comfort without costing the Earth. We will be unveiling our latest all-in-one Heat Pump, following years of development and welcome you to come and meet the team behind this innovative technology. From last years fundraise. The proceeds of the Investment will support the completion of the design and test phase and factory build for Ventive's modular heat pumps, further enhancements to its passive air ventilation product range, and build-up of its marketing and sales capacity to drive sales of its existing product range. The Ventive balance sheet is also streamlined following the conversion of the convertible loans. Following completion of the Investment, the total equity holding of the NetScientific group in Ventive is 11.0% on a fully diluted basis, which includes the partial settlement of its corporate finance fees relating to the Investment. This holding equates to a post-investment fair value of GBP893,000, a substantial increase of 1,617% from the GBP52,000 reported as at 31 December 2022. In addition, following the introduction of investors to Ventive by EMV Capital under its capital efficient model, NetScientific's capital under advisory with Ventive is now 23.8% of the fully diluted share capital. Ventive designs and manufactures intelligent heating and ventilation solutions to make buildings healthy, comfortable, efficient, and affordable. Its products address two high priority markets segments: air quality and sustainable heating. Ventive's passive air ventilation system has been delivered to over 30 schools and five leisure centres, achieving excellent air quality results. Its novel heat pump product, which is in advanced stages of development, is a comprehensive solution for residential applications, with a unique modular design and a novel thermal store. Momentum for the business is underpinned by significant regulatory changes, increasing energy prices, and climate change policies. |
Posted at 20/2/2024 22:57 by loafofbread ProAxsis announces strenghtening of Board and Update on StrategyTo expedite Point of Care range in respiratory diagnostics ProAxsis Limited, the Belfast-based diagnostics company in respiratory disease, is pleased to announce that is has strengthened its Board and updated its corporate strategy in line with its next phase of growth and market opportunities. Described as the ‘’gold standard in respiratory research’̵ The patient POC application will combine its patented NEATstik® with an integrated Remote Patient Monitoring platform to enhance patient outcomes, while delivering unparalleled value to healthcare providers. To that end, the company has strengthened its leadership team with relevant executive experience and is refocusing its resources to unlock the next stage of growth in the $5.8 billion global respiratory disease testing market.1 Appointment of new Chairperson and Non-Executive Director ProAxsis has appointed Alan Markey as its Chairperson. Alan brings significant expertise in MedTech to the company, having accumulated over 25 years of senior executive experience in the pharmaceutical and medical device sectors globally. Alan’s career spans senior roles at Johnson & Johnson, and Wyeth Pharmaceuticals (acquired by Pfizer). He has also served as MD of Baxter Healthcare, CEO of Noden Pharma DAC, and is a former Chairperson of HealthTech Ireland. His industry expertise and contacts will contribute significantly to the company’s strategy implementation. ProAxsis is also delighted to introduce Professor Steven Myint as a Non-Executive Director to the Board. Professor Myint is an internationally experienced Clinician, with past roles including Medical Director at GlaxoSmithKline and Senior Vice-President for R&D/Chief Medical Officer at BTG International. After his own first university spinout in 2005, he has been involved in the development of over 20 SMEs in life sciences and created over $1 billion value for shareholders. He is also a visiting Professor at the University of Surrey. Professor Myint’s insights and strategic guidance will be invaluable in shaping ProAxsis’s future. ProAxsis also announces that David Ribeiro, Chief Executive Officer, will be stepping down after nine years with the company to pursue another opportunity. The company continues to draw on the services and support of its key investor NetScientific PLC, a deep tech and life sciences VC investment group with an international portfolio of innovative companies. The company’s reorientation has further been supported by the investment facilitated by EMV Capital, the venture capital arm of NetScientific. Strategic Shift The global investment and international pharmaceutical company interest into respiratory diseases continues to grow alongside a drive for convenience, accelerated by the coronavirus pandemic. COPD is the third leading cause of death worldwide, and COPD cases are expected to grow from 480 million in 2020 to 660 million by 20502. In the UK alone, lung disease alone costs more than £11 billion per year, including the impact on the NHS (£9.9bn), and wider economy through working days lost (£1.2bn)3. ProAxsis is committed to remaining at the forefront of major developments and with its strategic shift towards Point of Care Testing (POCT), the company is bringing testing conveniently to the patient, potentially improving patient outcomes, clinician experience, and driving down healthcare costs to governments and insurance providers. The POCT will employ the company’s proprietary NEATstik technology to offer patients and healthcare providers novel solutions to prioritise patients with the highest immediate need. This will empower healthcare professionals to make quicker and more informed decisions and will enhance patient outcomes by: minimising avoidable exacerbations, reducing unnecessary clinic visits, and cutting down on extended hospital stays. The company intends to seek strategic alliances that will enable greater investment towards the development and expedited launch of its Patient Platform. Alan Markey, the new Chairperson of ProAxsis, commented: “I am honoured to join ProAxsis as Chairman during this exciting moment in the company’s journey. With a strong foundation in respiratory disease diagnostics and a renewed strategic focus on patient Point of Care testing, ProAxsis is poised to make further significant impact in improving patient outcomes and delivering value to healthcare providers. The Board extends gratitude to David for his leadership, dedication, and valuable contributions during his tenure, wishing him every success for the future. I look forward to working closely with the Board and wider management team to drive these initiatives and contribute to ProAxsis’s continued success.” Professor Steven Myint, the new Non-Executive Director of ProAxsis, added: “I am privileged to join ProAxsis as a Non-Executive Director and look forward to contributing my clinical and strategic insights to advance the company’s mission of improving patient outcomes in respiratory diseases. Through our focus on patient Point of Care Testing, powered by innovative and patented technology, we aim to empower healthcare providers with timely and accurate diagnostic solutions, ultimately enhancing patient care and quality of life.” |
Posted at 26/1/2024 09:55 by loafofbread Panmure Gordon were appointed to raise our profile and attract new investors.Assumed they would put out a decent note but still waiting. |
Posted at 15/11/2023 19:39 by kingston78 The following is an extract of an announcement by Cytovale reported by PR NewswireNov 15, 2023 1:03 PM GMT Cytovale Secures $84 Million Series C to Advance Commercialization of Transformative Sepsis Diagnostic Tool Norwest-led Financing Will Bring FDA-Cleared IntelliSep® Test to Hospitals Nationwide to Support Early Detection and Treatment of Serious Condition a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC). The financing included participation from other new and existing investors, as well as the conversion of bridge notes. Cytovale will use the proceeds to bring its – ® – to more hospital emergency departments (ED) and health systems in the United States, addressing historical diagnosis lag time that makes sepsis the leading cause of death in U.S. hospitals. |
Posted at 06/11/2023 18:34 by sev22 A technology sector bargain.A micro-cap investment company has announced a 17-fold increase in the carrying value of a portfolio company. November 6, 2023 by Simon Thompson *Portfolio company secures funding. *Massive increase in Netscientific’ *Portfolio fair valuation three times market capitalisation. Aim-traded investment company Netscientific (NSCI:52p) has announced the close of the first tranche of a £1mn-£1.5mn funding round for portfolio company Ventive. The investee company has secured a £0.9mn investment led by EMV Capital, Netscientific’ Ventive designs and manufactures intelligent heating and ventilation solutions to make buildings healthy, comfortable, efficient and affordable. Its products address two high-priority market segments: air quality and sustainable heating. Ventive’s passive air ventilation system has been installed in more than 30 schools and five leisure centres. Its novel heat pump product, which is in advanced stages of development, is a comprehensive solution for residential applications, with a unique modular design and a novel thermal store. Momentum for the business is underpinned by regulatory changes, high energy prices, and supportive climate change policies. For instance, Ventive recently secured a £0.1mn UK government grant focused on ‘net zero HVAC’ systems, having previously been awarded a £1.5mn Business, Energy and Industrial Strategy (BEIS) grant in 2022. The latest funding round included £0.32mn from existing shareholders and the conversion of £0.6mn of convertible loans into equity to streamline Ventive’s balance sheet. Ventive’s management expects to announce further investments from investors over the next six months, too. Bearing this in mind, EMV secured a 16 per cent stake in Ventive in partial settlement of its corporate fees in October 2022. EMV now retains an 11 per cent stake on a fully diluted basis that has a fair valuation of £0.9mn, or 17 times higher than the £52,000 carrying value in Netscientific’ I suggested buying Netscientific’ Furthermore, the £36.4mn (154p) pro-forma fair valuation of Netscientific’ |
Posted at 22/6/2023 08:50 by kingston78 In the announcement this morning, the following paragraph has caught my eye,"Alongside the new investors into Vortex, NetScientific converted its GBP0.4 million loan into equity. Following completion of the fundraising, the total equity holding of NetScientific in Vortex is now 24.98%, which equates to a post-investment fair value of GBP2.8 million, an increase of 300% from the GBP0.7 million reported as at 31 December 2022. In addition, following the introduction of investors to Vortex by EMVC (the wholly-owned subsidiary, and the corporate finance and venture capital arm, of NetScientific), the NetScientific capital under advisory with Vortex is 13.90% of the issued share capital." In my opinion this is an excellent corporate deal not only to introduce new investors to Vortex raising funds but also to put a value that external investors are willing to invest. Assuming NSCI can offload its shareholding in Vortex at this price it will have made 300% from £0.7 million to £2.8 million (a profit of £2.1 million). Vortex now has sufficient funds to carry on its business and NSCI makes a huge unrealised profit, without putting further sums of money into Vortex itself. This is magic. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
